You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
龍虎榜數據 | 眾生藥業漲停,2機構賣出1.45億元,聯泓新科獲深股通專用席位淨買入1.14億元。

今日兩市3021股下跌,1779股上漲,68只個股漲停,6只個股跌停。成交額8420億,北上資金淨賣出7.57億。盤面上,題材表現散亂,且活躍度不高,芯片、軍工、光伏、鋰電池、消費電子等主流題材跌幅靠前,歌爾股份連續兩天跌停,北方華創、立訊精密跌5%。旅遊、酒店餐飲、傳媒娛樂、釀酒、食品飲料等消費板塊漲幅靠前,供銷社概念午後稍有回落,天鵝股份強勢9連板;元宇宙、區塊鏈、智慧政務等概念活躍。

下面我們來看下今日龍虎榜情況:

今日龍虎榜淨買入額榜前三為賽騰股份、精華製藥、清水源,分別為7893.7萬元、6814.28萬元、6761.84萬元。

龍虎榜淨賣出額前三為眾生藥業、榕基軟件、聯泓新科,分別為2.81億元、1.45億元、9312.21萬元。

龍虎榜中涉及機構專用席位的個股中,當日淨買入額前三為僑源股份、羅諾醫療、羅曼股份,分別為4805.36萬元、3254.65萬元、2535.9萬元。

龍虎榜中涉及機構專用席位的個股中,當日淨賣出額前三為聯泓新科、眾生藥業、榕基軟件,分別為2.17億元、1.45億元、8819.68萬元。

眾生藥業關注點:

今日觸及漲停板,該股近一年漲停21次。

1、眾生藥業11月3日公吿,新冠創新藥RAY1216片獲得Ⅲ期臨牀試驗組長單位倫理批件。異煙肼片仿製藥質量和療效一致性評價的通過,是公司及華南藥業研發能力、生產及質量管理體系等綜合實力的體現。

2、公司主營業務是藥品研發、生產、銷售。公司主要產品有複方血栓通系列產品、眾生丸系列產品、頭孢克肟分散片、頭孢拉定膠囊、硫糖鋁口服混懸液。2021年,公司實現主營業務收入241,635.26萬元,同比上升27.98%,眼科醫療器械及耗材實現銷售85.46萬元,佔主營業務收入的0.04%。

榕基軟件關注點:

1、公司的主營業務為行業應用軟件研發、系統集成和運維服務。是華為優選級ISV夥伴、鯤鵬生態合作伙伴,目前公司與華為在企業網絡、數據中心、企業協作以及鯤鵬生態等領域有長期業務合作。

2、公司將發展自主可控信創業務作為企業核心戰略,由全資子公司榕基工程承擔,聚焦發展黨政機關協同辦公、電子公文、數字檔案、社會信用和公共服務以及司法、環保等優勢行業領域信創業務,是國內信創產業電子政務細分領域的先行者和領導者之一。

3、2017年1月23日晚間公吿,子公司榕基五一擬使用超募資金1500萬元投資建設VR體驗館項目,在全國範圍內建立一系列的VR體驗館,迅速形成設備+內容+運營的生態運營模式。

機構重點關注個股:

眾生藥業:2機構賣出1.45億元

僑源股份4機構買入5766.86萬元,1機構賣出961.51萬元

羅諾醫療1機構買入3254.65萬元

羅曼股份:3機構買入2535.9萬元

合鍛智能:3機構買入2529.64萬元

粵水電:1機構買入1970.88萬元,1機構賣出825.4萬元

在龍虎榜中,涉及滬股通專用席位的個股2只,賽騰股份的滬股通專用席位淨買入額最大,淨買入6728.33萬元。

在龍虎榜中,涉及深股通專用席位的個股有5只,聯泓新科的深股通專用席位淨買入額最大,淨買入1.14億元。

遊資操作動向:

寧波敢死隊許曉:淨買入眾生藥業3562.33萬元

寧波敢死隊馬信琪:淨買入眾泰汽車5703.69萬元、恩威醫藥395.13萬元

成都幫:淨買入天下秀2072.8萬元

趙老哥:淨買入中鋁國際981.19萬元;淨賣出天地在線2282.5萬元、羅曼股份1860.8萬元、科安達1131.83萬元

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account